However, they add that the combination of measurements from the tests of first and second quarter as higher detection rates and lower false positive rate.The new study was done by doctors including Fergal Malone, MD, of New York at Columbia University College of Physicians and Surgeons.
Test at 11 weeks of gestation was better than the second quarter of the screening, the researchers write. However, the tests performed before 13 weeks had similar results to the projection of the second quarter. Multiple trials
Each woman was only a child. Maternal age was considered. A total of 117 women were found in possession of a fetus with Down syndrome.
Combining the results of tests of each quarter also works well, researchers report in The New England Journal of Medicine. About Down Syndrome
A chromosomal abnormality in most cases is due to an extra copy of chromosome 21 in the third, or “trisomy 21″
Simpson is the staff at Baylor College of Medicine Department of Obstetrics and Gynecology. He also works at the Department of Molecular and Human Genetics at Baylor.
The National Institute of Child Health and Human Development provides this basic information about Down syndrome: the most common genetic cause of mild to moderate mental retardation and medical problems
They note that the tests of the second quarter was the current standard of care.
Malone’s team followed more than 38,000 women who were screened in their first trimester of pregnancy. The tests covered several clues about the likelihood that the child has Down syndrome.
Women and physicians may wish to consider the possibility of early diagnosis with a low rate of false positives and higher detection of a combination of tests, Malone and colleagues write.
“Pregnant women are now waiting the possibility of screening the first quarter,” writes Simpson. “If not available, it is prudent to allow the patient to go elsewhere.”
This is compared to that of the test was performed between 15-18 weeks. The types of testing differed between the two quarters. No game, a more invasive test that samples of fluid from the uterus.